Puma Biotechnology Inc - Çeyreklik Nakit Akışı (NASDAQ:PBYI) | MetaTrader

Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

Toplam varlıklar 213.33 M196.18 M194.92 M202.86 M216.3 M Toplam yükümlülükler 121.21 M99.07 M90.2 M87.59 M85.96 M Total equity 92.13 M97.11 M104.72 M115.27 M130.34 M Total liabilities & shareholders' equities 213.33 M196.18 M194.92 M202.86 M216.3 M Total debt 67.05 M55.98 M44.87 M33.72 M22.52 M Net debt -19.79 M-26.14 M-43.88 M-54.71 M-69.1 M

Puma Biotechnology Inc

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Haberler

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?

Puma Biotechnology 4Ç 2025: NERLYNX geliri %15 arttı

Puma Biotechnology güçlü 4Ç 2025 sonuçlarını açıkladı

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View

Puma Biotechnology, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-02-27

Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates

Puma Biotech kazancı $0,02 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates

Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates